Answers are grounded in this paper and cite their sources.
Randomized double-blind crossover trial demonstrates enhanced oral bioavailability of a catechin-complexed lipid nanocarrier in healthy subjects, indicating improved systemic delivery.
Phosphatidylserine (PS) is a neuroactive phospholipid whose oral delivery is limited by physicochemical instability and low systemic availability. This study developed and characterized Actiserine, a spray-dried lipid-based nanocarrier comprising a proposed catechin–phosphatidylserine complex stabilized with mannitol and arabinose, and evaluated its relative oral bioavailability in healthy subjects. Physicochemical characterization (FT-IR, PXRD, DSC, SEM, TEM, DLS, and ζ-potential analysis) demonstrated reduced crystallinity, favorable colloidal stability, and nanoscale vesicular structures. The formulation remained stable for 180 days under ICH-recommended refrigerated and long-term storage conditions. In a randomized, double-blind, two-period crossover pharmacokinetic study, plasma PS concentrations quantified by validated UPLC and confirmed by LC–MS/MS demonstrated a 3.39-fold higher AUC0–48h and 2.81-fold higher Cmax than conventional phosphatidylserine, with prolonged Tmax and elimination half-life. Actiserine represents a stable lipid-based PS delivery system with significantly improved relative oral bioavailability.
No takes yet. Share an insight, caveat, or question.
Amalraj et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: